Last Updated: August 3, 2026

Litigation Details for Entropic Communications, LLC v. DIRECTV, LLC (C.D. Cal. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Entropic Communications, LLC v. DIRECTV, LLC (C.D. Cal. 2022)

Docket 2:22-cv-07775 Date Filed 2022-10-25
Court District Court, C.D. California Date Terminated
Cause 35:271 Patent Infringement Assigned To John W. Holcomb
Jury Demand Both Referred To Karen E. Scott
Patents 11,040,018; 11,097,006; 8,106,022; 9,127,013
Link to Docket External link to docket
Small Molecule Drugs cited in Entropic Communications, LLC v. DIRECTV, LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Entropic Communications v. DIRECTV (2:22-cv-07775) Litigation Summary: Claims, Key Timeline, and What It Means for IP Risk

Last updated: July 4, 2026

Entropic Communications, LLC v. DIRECTV, LLC (case no. 2:22-cv-07775) is a US patent infringement dispute in which Entropic asserts infringement tied to its IP covering broadband video distribution and/or related delivery technologies used in DIRECTV’s satellite and video streaming environments. The docket in this case supports a standard US patent case lifecycle: pleadings, claim construction activity (or an early case management posture), and motion practice that typically culminates in a Markman schedule and later dispositive motions. The strongest business takeaway is that risk is driven by (1) claim scope tied to specific “system,” “method,” or “software” limitations and (2) whether DIRECTV’s accused products can be mapped to those limitations without falling into design-arounds.

What patents are asserted in Entropic v. DIRECTV?
No complete, accurate list of asserted patent numbers, publication numbers, and asserted claims can be produced from the information available in the prompt. Without the asserted-patent identifiers and the complaint’s claim list, any “which patents protect what” mapping would be speculative.

What is the procedural posture of Entropic v. DIRECTV (2:22-cv-07775)?
A litigation summary that is accurate to the docket requires docket-caption-level facts (complaint filing date, jurisdiction, parties and counsel, schedule, and whether motions were decided). The prompt provides only the case number and does not include docket entries or dates, which prevents a complete, reliable litigation timeline.

Who are the parties and what products are accused?
Only the parties “Entropic Communications, LLC” and “DIRECTV, LLC” and the case number “2:22-cv-07775” are provided. Accused DIRECTV offerings (specific platforms, head-end equipment, receivers, app builds, streaming devices, conditional access systems, or broadband transport components) are not provided, so claim-to-accused-product analysis cannot be completed without inventing facts.

Which court and venue is handling the case?
The prompt does not specify the court (district, judge, or magistrate), so any venue analysis (local rules, typical schedules, typical motion patterns, or infringement venue standards) would be incomplete.

What does the case signal for DIRECTV IP exposure?
A robust risk analysis depends on: asserted patent family strength, claim construction trends, and whether the case is filed alongside related matters (parallel cases against other multichannel video providers or OEM device partners). None of those inputs are included.

Litigation analysis framework (decision-useful, without making up case-specific facts)
Even without docket specifics, the investment-grade drivers in this type of dispute are consistent:

1) Claim construction risk is the main swing factor

Patent infringement cases with technical networking/video delivery patents usually hinge on whether the asserted claims require specific structural components, specific signaling/transport behaviors, or specific control logic. DIRECTV’s design-around likelihood depends on whether the claims can be satisfied through functional language or whether they are constrained by concrete limitations.

2) Infringement mapping is product-by-product and feature-by-feature

DIRECTV deployments commonly include multiple layers: content packaging, transport protocols, caching/ABR logic, receiver/decoder behavior, middleware, and session/auth flows. Courts typically require limitation-by-limitation mapping rather than general “uses this tech” arguments.

3) Validity challenges determine settlement economics

If DIRECTV can credibly challenge novelty and non-obviousness of the asserted claims, that pressures the settlement range. Conversely, if claim construction narrows the scope to embodiments already covered by strong disclosure and prosecution history, the bargaining posture improves for Entropic.

4) Remedies are constrained by availability of proof

Even when infringement is established, reasonable royalty and willfulness hinge on evidence: notice, internal assessments, infringement analysis, licensing discussions, and proof of damages methodology.

5) Procedural milestones drive business timing

The practical timeline for handset/TV platform rollouts and licensing negotiations is tied to Markman outcomes, dispositive motions, and any stays pending related ITC or parallel district cases. Without docket dates, no reliable commercial timetable can be stated.

Why a case-style summary is not complete here
The requested deliverable is “Litigation summary and analysis” for a specific docket. A complete, accurate summary requires at minimum: complaint filing date, court and judge, asserted patents and claims, accused DIRECTV products, and docket events (motions and outcomes). None of that case-anchoring information is included in the prompt, so a faithful litigation brief cannot be produced.


Key Takeaways

  • A litigation summary tied to case no. 2:22-cv-07775 requires asserted patent identifiers, complaint claim lists, and docket events; these are not present in the prompt.
  • Business risk in Entropic-style networking/video delivery disputes is driven primarily by claim construction scope and limitation-by-limitation infringement mapping to specific DIRECTV features.
  • Remedies and settlement posture depend on validity challenges, strength of technical evidence, and timing tied to Markman and dispositive motion outcomes.

FAQs

  1. How do courts in patent cases typically decide infringement for video delivery software claims?
  2. What evidence most often supports or defeats willfulness in telecommunications patent cases?
  3. How does Markman construction change settlement leverage in tech IP disputes?
  4. What damages methodologies are commonly used for streaming and video distribution patents?
  5. When can defendants seek stays pending parallel proceedings (ITC or related districts)?

References

  1. None.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.